1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?

 
• By Joseph Haas

Troubled since a miss in hidradenitis suppurativa last fall, Acelyrin’s izokibep succeeded in a psoriatic arthritis trial, but will the drug compete well against other IL-17 inhibitors?

Psoriatic arthritis
Acelryin hopes izokibep will be competitive in the PsA space • Source: Shutterstock

After disappointing its shareholders with Phase IIb/III data for IL-17a inhibitor izokibep in hidradenitis suppurativa (HS) last September, Acelyrin, Inc. reported Phase IIb/III data for the drug in psoriatic arthritis on 11 March that it claims will be competitive in that space, including a potential safety edge compared to a pair of investigational IL-17a/f inhibitors. Investors appeared to agree with the sentiment on 11 March, but at least one analyst said the PsA data do not look competitive.

Key Takeaways

  • Acelyrin hits its primary endpoint with izokibep in a Phase IIb/III study in psoriatic arthritis.

  • An IL-17a inhibitor, izokibep may compete with Cosentyx and...

In PsA, Acelyrin is eyeing both current and potential future competition, as Novartis AG’s Cosentyx (secukinumab) and Eli Lilly and Company’s Taltz (ixekizumab) are established IL-17 blockers in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

More from R&D

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback